indications
Last reviewed 01/2018
Cisapride was licensed for:
- symptoms and mucosal lesions associated with gastro-oesophageal reflux
- impaired gastric motility symptom relief secondary to systemic conditions:
- diabetes mellitus
- autonomic neuropathy
- systemic sclerosis
- short-term management of non-ulcer dyspepsia
- although cisapride is frequently used in children, particularly for the treatment of infantile gastro- oesophageal reflux, because of the risk of QT interval prolongation, cisapride is specifically contra - indicated in premature infants for up to 3 months after birth. Also in children up to the age of 12 years, there are insufficient data to support the use of cisapride.